Azacitidine - PubMed (original) (raw)

Azacitidine

Jean-Pierre Issa et al. Nat Rev Drug Discov. 2005 May.

Abstract

Azacitidine (Vidaza; Pharmion), an inhibitor of DNA methylation, was approved by the US FDA for the treatment of myelodysplastic syndromes in May 2004. It is the first drug to be approved by the FDA for treating this rare family of bone-marrow disorders, and has been given orphan-drug status. It is also a pioneering example of an agent that targets 'epigenetic' gene silencing, a mechanism that is exploited by cancer cells to inhibit the expression of genes that counteract the malignant phenotype.

PubMed Disclaimer

Similar articles

• Azacitidine.
  Issa JP, Kantarjian HM, Kirkpatrick P. Issa JP, et al. Nat Rev Drug Discov. 2005 Apr;4(4):275-6. doi: 10.1038/nrd1698. Nat Rev Drug Discov. 2005. PMID: 15861567 No abstract available.
• [Pharmacological profiles and clinical roles of 5-azacitidine (Vidaza(®) for injection 100 mg) for the treatment of myelodysplastic syndrome (MDS)].
  Takahashi Y, Kimura S, Okano M. Takahashi Y, et al. Nihon Yakurigaku Zasshi. 2012 Nov;140(5):235-43. doi: 10.1254/fpj.140.235. Nihon Yakurigaku Zasshi. 2012. PMID: 23138323 Review. Japanese. No abstract available.
• FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
  Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R. Kaminskas E, et al. Oncologist. 2005 Mar;10(3):176-82. doi: 10.1634/theoncologist.10-3-176. Oncologist. 2005. PMID: 15793220 Review.
• Safety and efficacy of azacitidine in myelodysplastic syndromes.
  Vigil CE, Martin-Santos T, Garcia-Manero G. Vigil CE, et al. Drug Des Devel Ther. 2010 Sep 24;4:221-9. doi: 10.2147/dddt.s3143. Drug Des Devel Ther. 2010. PMID: 20957213 Free PMC article. Review.
• Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
  Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL, Leighton JK, Patel H, Rahman A, Sridhara R, Wang YC, Pazdur R; FDA. Kaminskas E, et al. Clin Cancer Res. 2005 May 15;11(10):3604-8. doi: 10.1158/1078-0432.CCR-04-2135. Clin Cancer Res. 2005. PMID: 15897554 Clinical Trial.

Cited by

• Transcriptional repressive H3K9 and H3K27 methylations contribute to DNMT1-mediated DNA methylation recovery.
  Wong CM, Wong CC, Ng YL, Au SL, Ko FC, Ng IO. Wong CM, et al. PLoS One. 2011 Feb 8;6(2):e16702. doi: 10.1371/journal.pone.0016702. PLoS One. 2011. PMID: 21347439 Free PMC article.
• 5-Aza-2'-deoxycytidine is a potent inhibitor of DNA methyltransferase 3B and induces apoptosis in human endometrial cancer cell lines with the up-regulation of hMLH1.
  Cui M, Wen Z, Chen J, Yang Z, Zhang H. Cui M, et al. Med Oncol. 2010 Jun;27(2):278-85. doi: 10.1007/s12032-009-9204-1. Epub 2009 Mar 21. Med Oncol. 2010. PMID: 19306077
• Epigenetic regulation of human FOXP3+ Tregs: from homeostasis maintenance to pathogen defense.
  Yue Y, Ren Y, Lu C, Li P, Zhang G. Yue Y, et al. Front Immunol. 2024 Jul 31;15:1444533. doi: 10.3389/fimmu.2024.1444533. eCollection 2024. Front Immunol. 2024. PMID: 39144146 Free PMC article. Review.
• The association between methylated CDKN2A and cervical carcinogenesis, and its diagnostic value in cervical cancer: a meta-analysis.
  Li J, Zhou C, Zhou H, Bao T, Gao T, Jiang X, Ye M. Li J, et al. Ther Clin Risk Manag. 2016 Aug 18;12:1249-60. doi: 10.2147/TCRM.S108094. eCollection 2016. Ther Clin Risk Manag. 2016. PMID: 27574435 Free PMC article.
• 5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1.
  Dapp MJ, Clouser CL, Patterson S, Mansky LM. Dapp MJ, et al. J Virol. 2009 Nov;83(22):11950-8. doi: 10.1128/JVI.01406-09. Epub 2009 Sep 2. J Virol. 2009. PMID: 19726509 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information